OBIO

Orchestra BioMed

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 2

consensus rating "Strong Buy"

EPS Below Expectations

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About OBIO

Orchestra Biomed Holdings, Inc.

A therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases

Industry

Healthcare Equipment and Supplies

Established Date

05/25/2020

Listing Date

08/04/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

investors.orchestrabiomed.com

Security Type

Common stock

Office address

150 Union Square Drive, New Hope, Pennsylvania 18938

Business

Introduction

Orchestra BioMed Holdings, Inc., incorporated in Delaware on May 25, 2020, is a biomedical innovation company that accelerates the development of high-impact technologies for patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's collaborative business model focuses on establishing strategic partnerships with leading medical device companies to drive the successful commercialization of the products they develop globally. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy for the treatment of hypertension, a significant risk factor for death worldwide, Virtue Sirolimus AngioInfusion Balloon (SAB) is used to treat atherosclerotic artery disease, which is the leading cause of death worldwide. Orchestra BioMed has entered into a strategic partnership with Medtronic, one of the largest medical device companies in the world, to develop and commercialize BackBeat CNT for the treatment of high blood pressure in patients indicated by pacemakers, and Virtue SAB for the treatment of arterial disease.

Company Financials

EPS

OBIO has released its 2024 Q4 earnings. EPS was reported at -0.43, versus the expected -0.42, missing expectations. The chart below visualizes how OBIO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

OBIO has released its 2024 Q4 earnings report, with revenue of 253.00K, reflecting a YoY change of -3.44%, and net profit of -16.16M, showing a YoY change of -26.03%. The Sankey diagram below clearly presents OBIO’s revenue sources and cost distribution.